Oxford Nanopore Technologies Ltd (ONT)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 210.40 |
|---|---|
| 52-week range | 95.61 – 238.80 |
| Return, 1 month / 3 months | +19.9% / +95.4% |
| Return, 1 year / 3 years | +45.8% / −6.2% |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 59.8% |
| Worst drawdown (1 year) | -39.6% |
| Average daily value traded | 546.36M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Oxford Nanopore Technologies designs and makes devices that read DNA and RNA using nanopore sensing technology. Its sequencers, including portable and benchtop instruments, are used by scientists in research institutes, universities, clinical laboratories and other organisations that study genetics and disease. The company also supplies the consumable flow cells and software that go with its instruments. Oxford Nanopore Technologies is based in Oxford, in the United Kingdom, and serves customers in many countries around the world.
On this site Oxford Nanopore Technologies Ltd appears as a stock on the London Exchange (UK), code ONT, with prices in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Oxford Nanopore Technologies Ltd (ONT) trades on the London Exchange in UK. It last closed at GBX 210.40 on 23 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 379 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 45.8% and over the last three months it rose 95.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 89 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 50.4% | ||
| From 52-week high | -8.8% | ||
| Momentum | 89 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 95.4% | ||
| 6-month return | 82.5% | ||
| 12-month return, skipping the last month | 21.6% | ||
| Stability (higher is calmer) | 26 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 59.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.6% | ||
| Liquidity | 96 · Strong | Trades actively. | |
| Average daily value traded | 546.36M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +5.2% |
|---|---|
| 1 month | +19.9% |
| 3 months | +95.4% |
| 6 months | +82.5% |
| 1 year | +45.8% |
| 3 years | −6.2% |
| 5 years | −59.9% |
Signals
| 50-day / 200-day average | 182.08 / 139.93 |
|---|---|
| Golden / death cross (60 days) | Golden, 36 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 11.96 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.